These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 3488923)
1. Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2. Bubeník J; Kieler J; Tromholt V; Steven K; Indrová M; Toulcová A Folia Biol (Praha); 1986; 32(3):183-94. PubMed ID: 3488923 [TBL] [Abstract][Full Text] [Related]
2. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). Mizutani Y; Yoshida O; Bonavida B J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929 [TBL] [Abstract][Full Text] [Related]
10. [Serum factors present in patients with carcinoma of the bladder: effect on cell-mediated immunity]. de la Fuente M; Aranda E; Molina I; Sánchez Guijo P; Peña J Rev Esp Oncol; 1984; 31(2):257-64. PubMed ID: 6336253 [TBL] [Abstract][Full Text] [Related]
11. [Dynamics of cytotoxicity of blood mononuclear cells in patients with bladder cancer during endolymphatic immunotherapy with lymphokine- activated killer cells and recombinant interleukin-2]. Malakhova NV; Figurin KM; Fedorova NS; Kiselevskiĭ MV; Bykovskaia SN Biull Eksp Biol Med; 1996 Feb; 121(2):188-91. PubMed ID: 9026128 [No Abstract] [Full Text] [Related]
12. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood. Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of soluble Fas in the serum of patients with bladder cancer. Mizutani Y; Yoshida O; Bonavida B J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930 [TBL] [Abstract][Full Text] [Related]
14. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts. Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628 [TBL] [Abstract][Full Text] [Related]
15. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma. Hermann GG APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200 [No Abstract] [Full Text] [Related]
16. In vitro generation of bacillus Calmette-Guérin-activated killer cells. Brandau S; Böhle A; Thanhäuser A; Ernst M; Mattern T; Ulmer AJ; Flad HD Clin Infect Dis; 2000 Sep; 31 Suppl 3():S94-S100. PubMed ID: 11010832 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. Hinuma S; Naruo K; Shiho O; Tsukamoto K Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435 [TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of murine sarcomas with interleukin 2. II. Activation of killer cells by human recombinant IL-2. Indrová M; Bubeník J; Toulcová A Folia Biol (Praha); 1986; 32(6):392-8. PubMed ID: 3492397 [TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor. Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]